Prana Biotechnology secures FDA orphan drug status for PBT434 to treat multiple system atrophy

In a significant milestone, Prana Biotechnology, an Australian biotech company, has obtained Orphan Drug designation from the FDA for PBT434, its lead molecule aimed at ... Read More